Michael di Giovanna, DO
Internal Medicine · North Massapequa, NYNPI 1043222755
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.7%. Reporting peaked in 2019 at $20,194 and has fallen 89.2% since, to $2,185 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 800 payments — averaging $84.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- Pfizer$7K
- Lilly USA, LLC$6K
- Novartis$6K
- Eli Lilly$5K
- AstraZeneca$5K
- plus $27K from 54 others
Across 247 payments — averaging $5263.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$721K
- Pfizer$148K
- Bristol Myers Squibb$103K
- Takeda Pharmaceuticals U.S.A., Inc.$60K
- Biohaven Pharmaceutical Holding Company Ltd.$53K
- Janssen Research & Development, LLC$39K
- plus $176K from 9 others
What the payments were for
- Consulting fees$34,93652%
- Speaking & faculty fees$4,1856%
- Travel & lodging$10,62516%
- Food & beverage$17,68326%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$6,479
- BEVESPI AEROSPHERE$4,850
- PAXLOVID$4,170
- Repatha$3,003
- LEQVIO$2,113
- KESIMPTA$1,855
- AIMOVIG$1,484
- ENTRESTO$1,484
- TOUJEO$1,434
- Tremfya$1,026
- FARXIGA$896
- UBRELVY$800
- MOUNJARO$363
- DISEASE STATE$248
- Inspire$245
- ZEPBOUND$238
- Ozempic$237
- AJOVY$130
- Inspire Upper Airway Stimulation System$128
- VRAYLAR$125
How this compares
$67,541 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 172 | $246,461 |
| OzempicSemaglutide | 136 | $183,489 |
| StelaraUstekinumab | 12 | $164,381 |
| TrulicityDulaglutide | 80 | $115,134 |
| JardianceEmpagliflozin | 83 | $91,182 |
| FarxigaDapagliflozin Propanediol | 60 | $80,542 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $71,631 |
| RybelsusSemaglutide | 27 | $48,297 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $40,646 |
| KerendiaFinerenone | 41 | $39,942 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 34 | $39,102 |
| JanuviaSitagliptin Phosphate | 25 | $38,503 |
| XareltoRivaroxaban | 22 | $34,623 |
| EliquisApixaban | 22 | $27,018 |
| LinzessLinaclotide | 22 | $17,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $6,145 | $361,595252 claims |
| Novo NordiskOzempic, Rybelsus | $1,538 | $231,786163 claims |
| Johnson & JohnsonStelara, Xarelto | $110 | $199,00334 claims |
| Boehringer IngelheimJardiance | $532 | $91,18283 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $4,746 | $87,70872 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $728 | $67,193126 claims |
| BayerKerendia | $349 | $39,94241 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11,929 | $39,10234 claims |
| MerckJanuvia | $379 | $38,50325 claims |
| PfizerEliquis | $6,614 | $27,01822 claims |
| AbbVieLinzess, Synthroid | $2,283 | $20,48362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in North Massapequa
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.